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Muscular dystrophy is a progressive disease of muscle weakness, muscle atrophy
and cardiac dysfunction. Patients afflicted with muscular dystrophy exhibit autonomic
dysfunction along with cognitive impairment, severe depression, sadness, and anxiety.
Although the psychological aspects of cardiovascular disorders and stress disorders
are well known, the physiological mechanism underlying this relationship is not well
understood, particularly in muscular dystrophy. Therefore, the goal of this perspective is
to highlight the importance of autonomic dysfunction and psychological stress disorders
in the pathogenesis of muscular dystrophy. This article will for the first time—(i) outline
autonomic mechanisms that are common to both psychological stress and cardiovascular
disorders in muscular dystrophy; (ii) propose therapies that would improve behavioral and
autonomic functions in muscular dystrophy.
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Muscular dystrophy is a devastating neuromuscular disorder that
is currently without an effective therapy. It is characterized by
progressive increase in muscle weakness and muscle wasting.
Myocardial disease, manifesting predominantly as dilated car-
diomyopathy (DCM) and congestive heart failure or conduction
system abnormalities have been observed in many muscular dys-
trophies. Evidence of an association between vulnerability to
lethal arrhythmias and signs of either increased sympathetic or
reduced parasympathetic tone as quantitative markers of auto-
nomic activity in muscular dystrophy are becoming increasingly
recognized in patients and animals (Groh, 2012; Russo et al.,
2012).
The physical and social hardships associated with the dis-
ease often lead to psychological stress disorders such as depres-
sion and anxiety, in muscular dystrophy patients. Psychological
stress affects both mental and physical health. Depressed patients
with or without a history of cardiovascular pathology display
signs such as elevated heart rate (HR), reduced HR variability
(HRV), and increased physiological reactivity to environmen-
tal stressors which may cause predisposition to cardiovascular
events. Converging evidence from experimental and epidemio-
logical studies indicate that there is a bidirectional association
between psychological stress and cardiac risk, such that pres-
ence of one increases the likelihood of developing the other
(Penninx et al., 2001; Freedland et al., 2003; Johnson and Grippo,
2006). Although psychological stress disorders are prevalent in
patients with muscular dystrophy, their physiological and patho-
physiological consequences on disease progression have received
little attention. The focus of this perspective is to demonstrate
that synergistic actions of autonomic dysregulation and psy-
chological stress may exacerbate disease progression in muscu-
lar dystrophy and identify strategies to yield better therapeutic
outcomes.
AUTONOMIC DYSREGULATION IN MUSCULAR DYSTROPHY
Evidence of aberrant autonomic signaling has been demonstrated
in both patients and animals with Duchenne, Becker, myotonic
type 1 (DM1) muscular dystrophy. HRV, as a quantitative marker
of parasympathetic tone, is decreased in muscular dystrophies
(Politano et al., 2008; Inoue et al., 2009; Della Marca et al., 2010).
It has been suggested that activation of the renin angiotensin
system (RAS) contributes to the pathological changes occur-
ring in muscular dystrophy (Cohn et al., 2007; Sun et al., 2009;
Sabharwal et al., 2010a; Cabello-Verrugio et al., 2012). Previous
work has provided evidence of autonomic dysregulation and loss
of exercise-induced sympatholysis in muscular dystrophy (Sander
et al., 2000). Furthermore, treatment of muscular dystrophy
patients with angiotensin converting enzyme inhibitors (ACEi)
and β-blockers has been shown to delay onset of DCM (Dubuc
et al., 2005; Blain et al., 2013). These studies led us to determine
the importance of autonomic dysregulation in pathogenesis of
muscular dystrophy. We did so by utilizing an established mouse
model of limb girdle muscular dystrophy (LGMD).
Dystrophin glycoprotein complex (DGC) is composed of mul-
tiple proteins that form a physical linkage between the intra-
cellular and extracellular matrix. Sarcoglycans are important
component of the DGC that protects cell membrane against
forces generated during muscle contraction (Straub et al., 1998).
Mutation in sarcoglycan delta (Sgcd) causes LGMD-2F. We
found that young Sgcd deficient mice (Sgcd−/−) exhibit severe
autonomic dysregulation (reduced HRV, impaired baroreflex
function, sympatho-vagal imbalance) before left ventricular (LV)
dysfunction (Sabharwal et al., 2010b). Furthermore, we found
that the severity of autonomic dysregulation in young Sgcd−/−
mice predicts severity of LV dysfunction and mortality at older
ages (Sabharwal et al., 2010b). We speculate that the combined
effects of chronic autonomic dysfunction and psychological stress
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provoke arrhythmias in muscular dystrophy; the latter has been
recognized as a common cause of mortality in muscular dystro-
phy (Groh, 2012; Russo et al., 2012).
PSYCHOLOGICAL STRESS IN MUSCULAR DYSTROPHY
The association of intellectual impairment with Duchenne
muscular dystrophy has long been recognized. Recent studies
have demonstrated psychiatric disorders such as autism, dys-
thymic and clinical depression are fairly common in patients
afflicted with DM1, Duchenne, LGMD, and facioscapulo-
humeral muscular dystrophies (Fitzpatrick et al., 1986; Douniol
et al., 2009; Winblad et al., 2013). Children with muscu-
lar dystrophy not only face inevitable deterioration of phys-
ical functioning, but also become susceptible to emotional
and behavioral problems, mental alteration mainly character-
ized by poor verbal Intelligence Quotient, memory, and cog-
nitive deficits, and reading disabilities (Billard et al., 1992;
Polakoff et al., 1998). These deficits are without histopatholog-
ical abnormalities in the brain (Dubowitz and Crome, 1969;
Billard et al., 1992). The mdx mouse is a widely used exper-
imental model of human Duchenne muscular dystrophy. In
addition to skeletal muscle weakness and reduced locomo-
tor activity, mdx mice exhibit disruption in synaptic plasticity,
reduced long-term potentiation in Purkinje cells, learning, and
memory deficits along with enhanced anxiety-related and defen-
sive freezing behavior (Anderson et al., 2004; Sekiguchi et al.,
2009).
In DM1, heart conduction defects, endocrine dysfunction and
brain abnormalities such as cerebral atrophy and white matter
lesions are fairly common (Meola and Sansone, 2007). DM1 is
associated with cognitive deficits, depression, anxiety, mood, and
personality disorders (Meola and Sansone, 2007). Similarly, mice
with deletion of muscleblind-like 1 (Mbnl1), a RNA splice reg-
ulator that causes DM1, exhibit cognitive impairment, learning,
and memory deficits, and behavioral abnormalities (depression,
autism, anxiety) (Matynia et al., 2012).
Peripartum cardiomyopathy is LV dysfunction that presents
toward the end of pregnancy or in the months just after deliv-
ery. Women afflicted with muscular dystrophy and psychologi-
cal stress disorders are at a greater risk to develop peripartum
cardiomyopathy. Recently, two cases of postpartum cardiomy-
opathy have been reported in previously asymptomatic carriers
of Duchenne muscular dystrophy (Davies et al., 2001; Cheng
and Prior, 2013). Women with peripartum cardiomyopathy have
reduced levels of signal transducer and activator of transcrip-
tion 3 (STAT3), increased cathepsin D, and decreased expression
of manganese superoxide dismutase; the combination of which
causes apoptosis, impaired angiogenesis, and oxidative stress.
Bromocriptine, that blocks the release of prolactin from the pitu-
itary gland, has been reported to decrease morbidity and mortal-
ity in this condition (Sliwa et al., 2010), although this is yet to be
confirmed.
Whilst physiological mechanisms of psychological stress are
largely unknown, these association studies demonstrate high
prevalence of stress disorders in muscular dystrophies. There
is mounting evidence that psychological stress plays a critical
role in triggering cardiac arrhythmias and sudden cardiac death.
Therefore, it becomes imperative to determine the underlying
mechanisms of these dysfunctions.
PROPOSED MECHANISMS OF AUTONOMIC DYSFUNCTION
AND PSYCHOLOGICAL STRESS IN MUSCULAR DYSTROPHY
Depression has been characterized by activation of the sympa-
thetic nervous system and withdrawal of parasympathetic tone
to the heart, increased resting HR and reduced HRV (Lahmeyer
and Bellur, 1987; Barton et al., 2007). In humans, 24-h elec-
trocardiogram provides a useful strategy for investigating auto-
nomic consequences of depression and predictors of mortality
(Aronow et al., 1996; Guzzetti et al., 2005). Cardiac nore-
pinephrine spillover, activation of sympathetic nervous system
and reduced neuronal reuptake of norepinephrine predispose to
the development of cardiac arrhythmias in psychological disor-
ders (Esler et al., 2004; Barton et al., 2007). Chronic stress can
also evoke arrhythmias by altering stability of cardiac repolariza-
tion (Carney et al., 2003; Lampert et al., 2005). Lambert et al.
suggest that the sympathetic neurons fire more often in multi-
ple spike pattern in patients with panic disorders (Lambert et al.,
2006).
Some of the reflexes that could be important in regulating sym-
pathetic and parasympathetic outflow in muscular dystrophy are
baroreceptor reflexes, skeletal muscle afferent reflex, and cardiac
vagal afferent reflex (Figure 1). Baroreceptors are mechanosen-
sitive nerve endings located in carotid sinuses and aortic arch
that function as blood pressure sensors. Changes in baroreceptor
activity evoke reflex changes in parasympathetic and sympathetic
activity (Chapleau et al., 2001; Head and Mayorov, 2001; Stauss,
2002). Reduced baroreflex gain can contribute to cardiovascu-
lar morbidity and mortality via reduction in parasympathetic
activity, an increase in sympathetic activity, or both. There are
several reports whereby reduced baroreflex gain and depres-
sion increase the risk of ventricular fibrillation (Billman et al.,
1982; Schwartz et al., 1988; Watkins and Grossman, 1999). Rats
exposed to a series of chronic mild stressors exhibit anhedonia
(an essential feature of human depression), reduced baroreflex
function, elevated HR, decreased HRV, and exaggerated pressor
and HR responses to air jet stress (Grippo et al., 2002, 2008).
Mechanoreceptors located in the heart and cardiopulmonary
region sense changes in central blood volume through their sen-
sitivity to cardiac and vascular distension. In heart failure or
DCM (as seen in advanced stages of muscular dystrophy), the
mechanosensitivity of cardiac vagal afferents is severely depressed
which can contribute to an increase in sympathetic tone, decrease
in parasympathetic tone, and fluid retention (Walgenbach and
Shepherd, 1984; DiBona and Sawin, 1995). Another neural mech-
anism that is likely to be important in muscular dystrophy is
the somatic afferent reflex. Group III and IV muscle afferents
are activated by changes in pH, inflammatory mediators, oxida-
tive stress and/or by abnormal mechanical coupling between
muscle and sensory nerve endings to evoke reflex increases in
sympathetic activity, inhibition of parasympathetic activity, and
decrease in baroreflex gain (Delliaux et al., 2009; Kaufman,
2012).
Stressful stimuli of different modalities activate sympatho-
adrenal and hypothalamic-pituitary (HPA) axes (Badoer, 2001).
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FIGURE 1 | Possible mechanisms involved in autonomic dysfunction and
psychological stress in muscular dystrophy. Sensory input by the
baroreceptor afferents, cardiac vagal afferents, and skeletal muscle afferents
are integrated within the brain to modulate parasympathetic and sympathetic
outflows. Disturbances in the sensory inputs and/or central integration and
neurotransmission may contribute to autonomic dysregulation and
psychological stress in muscular dystrophy. SNA, sympathetic nerve activity;
ParaSNA, parasympathetic nerve activity; RAS, renin angiotensin system;
CRH, corticotrophin releasing hormone; HRV, heart rate variability; HR, heart
rate; BRS, baroreflex sensitivity; (−), inhibition; (+), excitation.
It is now well established that the dorsomedial hypothala-
mus is a key area involved in integrating neurally-mediated
cardiovascular responses to psychological stress. This area receives
synaptic inputs from many regions of the brain that are acti-
vated during stress including periaqueductal gray, amygdala,
raphe pallidus, rostroventral, and caudal portions of the lat-
eral medulla, hippocampus, and the nucleus of the solitary
tract (Cechetto and Chen, 1990; Hunt et al., 2010; Xavier
et al., 2013). Some of the neurotransmitters involved in car-
diovascular and behavioral responses to stress are serotonin,
catecholamines, dopamine, histamine, oxytocin, vasopressin,
angiotensin II, corticotrophin releasing hormone, the cytokines
IL-1β, and TNF-α etc. (Mayorov and Head, 2003; Wsol et al.,
2008). It is noteworthy that several proteins belonging to the
DGC and involved in muscular dystrophies (dystroglycans, dys-
trophin, sarcoglycans) have now been identified in forebrain,
midbrain, and brainstem (Anastasi et al., 2012; Waite et al.,
2012).
It is important to emphasize that mechanisms of autonomic
dysfunction or psychological stress in muscular dystrophy are
yet to be identified. Figure 1 thus provides a simplistic overview
of possible pathways/mechanisms that may contribute to the
pathogenesis of this disease.
THERAPEUTIC TARGETS TO IMPROVE AUTONOMIC
FUNCTION AND REDUCE PSYCHOLOGICAL STRESS
The RAS is activated in muscular dystrophy (Sun et al., 2009;
Sabharwal et al., 2010a; Cabello-Verrugio et al., 2012). RAS is
comprised of two axes—vasoconstrictor angiotensin II (Ang II)
acts primarily via Ang II type 1 receptors (AT1R) and the vasodila-
tor Ang-(1–7) peptide acting on Mas receptors (Bader et al.,
2012). Ang II also acts on type 2 receptors (AT2R). Angiotensin
receptor blockers (ARBs) and ACEi are used clinically in mus-
cular dystrophy and dilated cardiomyopathy (Dubuc et al., 2005;
Cohn et al., 2007). It is well known that Ang II is a major stress
hormone (DuboYang et al., 1993). ARBs and ACEi are also used
in treating conditions like mood disorders, depression, and neu-
rodegenerative and traumatic disorders of the brain (Bostwick,
2010). Systemic administration of candesartan/losartan can abro-
gate behavioral responses to acute and long-term isolation stress
(Baiardi et al., 2004; Armando et al., 2007), cold restraint stress
(Bregonzio et al., 2008), and forced swim test (Martin et al.,
1990) in rodents. ARBs and ACEi have also been shown to be
effective in reducing brain inflammation associated with depres-
sion (Young et al., 2003; Munoz et al., 2006). Psychological stress
reduces expression of central AT2R receptors and animals lacking
AT2R develop anxious behavior (Hein et al., 1995; Ichiki et al.,
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1995). These studies suggest that centrally acting AT2R agonists
may serve as potential anxiolytic agents. More recently, Ang-
(1–7) has also been suggested to exert anxiolytic actions. Bild
et al demonstrated that rats treated with Ang-(1–7) performed
better in the maze test than the untreated animals (Bild and
Ciobica, 2013). Furthermore, mice lacking Mas receptors display
increased anxiety (Walther et al., 1998), and activation of the
Ang-(1–7)/Mas axis attenuates stress-induced tachycardia in rats
(Martins Lima et al., 2013). These studies suggest that drugs tar-
geting the RAS [Ang-(1–7)/Mas, AT2R agonists, ACEi, or ARBs]
may improve outcomes in muscular dystrophy not only through
their direct autonomic/cardiovascular effects but also via their
anxiolytic actions.
Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter
that modulates stress responses by interacting with the HPA axis
and sympathetic nervous system (Chrousos, 2009). Selective sero-
tonin reuptake inhibitors (SSRI) and serotonin norepinephrine
reuptake inhibitors (SNRI) are used for treatment of depression
and anxiety (Glassman et al., 2002; Trivedi et al., 2006). SSRIs
exert their effects via modulating monoaminergic signaling or
via their anti-inflammatory actions (Walker, 2013). SSRIs are
considered safe even when administered to patients with seri-
ous cardiovascular diseases (Glassman et al., 2002; Taylor et al.,
2005). SSRIs reduce depressive symptoms, increase HRV, reduce
inflammatory markers, normalize urinary cortical excretion, and
reduce plasma catecholamine levels (Glassman et al., 2002). Loss
of central 5-HT neurons may cause hypersomnia in patients with
myotonic dystrophy (Ono et al., 1998). SSRI therapy can also
revert abnormal electromyogram in myotonic dystrophy type 1
(Chisari et al., 2009), and improve psychiatric comorbidities
in Becker muscular dystrophy (Chaichana et al., 2007). Thus,
SSRI therapy may improve outcomes in muscular dystrophy via
multiple mechanisms.
SUMMARY
Muscular dystrophy is a catastrophic disease which is character-
ized by progressive muscle weakness and wasting, cardiomyopa-
thy, and early mortality. Patients with muscular dystrophy are
commonly afflicted with psychological disorders like depression,
anxiety, cognitive deficits etc., which likely exacerbates disease
progression and worsens the quality of life. Both muscular dys-
trophy and behavioral disorders are associated with autonomic
dysregulation. In view of the devastating outcome of muscular
dystrophy most attention has been directed toward improving
muscle function and structure. However, treating both autonomic
dysregulation and stress disorders is recommended for patients
with muscular dystrophy. Additive and synergistic actions are
likely to result in better therapeutic outcomes.
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